Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CRB-701 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- CSPC Pharmaceutical Group
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CRB-701 + anti-PD-1 is a combination therapy comprising CRB-701, a next-generation antibody-drug conjugate (ADC) targeting Nectin-4, and an anti-PD-1 checkpoint inhibitor, specifically pembrolizumab. CRB-701 (also known as SYS6002) utilizes a site-specific, cleavable linker to attach a monomethyl auristatin E (MMAE) cytotoxic payload to a Nectin-4-directed antibody with a drug-antibody ratio (DAR) of 2. This combination aims to leverage the direct tumor-killing effects of the ADC and the immune-potentiating effects of PD-1 blockade. It is currently being evaluated in Phase 1/2 clinical trials for advanced solid tumors, including head and neck squamous cell carcinoma (HNSCC), cervical cancer, and metastatic urothelial cancer.
- Other names
- CRB-701 + anti-PD-1SYS6002 + pembrolizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)NeuraminidaseFcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)TUBB (Tubulin (alpha and beta subunits))PVRL4 (Nectin cell adhesion molecule 4)
Beyond the preview
Go deeper on CRB-701 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CRB-701 + pembrolizumab.